Objective To assess the prevalence of non-superficial surgical site infection (NSSSI) in patients with total hip arthroplasty (THA) and the influencing factors. Method The PubMed, the Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), Weipu database and Wanfang database were systematically searched from 2016 to 2021. The data were collected from the included studies that met the inclusion criteria. For exploring the prevalence of NSSSI with THA, the pooled prevalence and its 95% confidence intervals (CI) were calculated. Publication bias was assessed. In the study of the association between potential influencing factors and infection, the odds ratio and its 95% CI were calculated. Results In all, 57 studies involving 2075304 patients were included. The number of patients receiving THA ranged from 87 to 623253, and the prevalence of patients with NSSSI after THA ranged from 0.05% to 9.13%. The meta-analysis results showed that the prevalence of patients with NSSSI after THA was 1.0% (95% CI: 0.8%, 1.1%). No publication bias was found under Begg’s test (z=0.28, p>0.05) or Egger's test (t=1.65, p>0.05). When stratified by data scale, pooled prevalence of studies with large-scale data and that of studies with normal-scale data were similar (large-scale: 0.9% (95%CI: 0.6%-1.3%); normal-scale: 1.1% (95%CI: 0.9%-1.2%), respectively). When stratified by country, the prevalence of different countries was of various. Individual results showed that the prevalence of Netherlands was the highest (9.5%) and that of New Zealand was the lowest (0.1%). Pooled results showed that China had the highest prevalence of 2.2% (95%CI: 1.8%-2.7%), and UK had the lowest prevalence of 0.3% (95%CI: 0.0%-0.6%). Ten influencing factors of NSSSI in patients with THA were recognized (p<0.05), including male, tobacco smoker, body mass index, diabetes mellitus, American Society of Anesthesiologists grade III or IV or V, serum albumin <3.5 g/dL, immunosuppressive agent user, universal anesthesia, non-vancomycin powder user, and duration of drain >48h.Conclusion The pooled prevalence of NSSSI in patients after THA was 1.0% and 10 potential factors were associated with the prevalence. We provide clinical guidance to prevent NSSSI after THA.